BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 20124451)

  • 1. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
    Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
    Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
    Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
    Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
    Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
    Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1.
    Paul S; Roy A; Deka SJ; Panda S; Trivedi V; Manna D
    Eur J Med Chem; 2016 Oct; 121():364-375. PubMed ID: 27267006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.
    Takamatsu M; Hirata A; Ohtaki H; Hoshi M; Ando T; Ito H; Hatano Y; Tomita H; Kuno T; Saito K; Seishima M; Hara A
    Cancer Sci; 2015 Aug; 106(8):1008-15. PubMed ID: 26033215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
    Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
    Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
    Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors.
    Naing A; Eder JP; Piha-Paul SA; Gimmi C; Hussey E; Zhang S; Hildebrand V; Hosagrahara V; Habermehl C; Moisan J; Papadopoulos KP
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research progress of indoleamine 2,3-dioxygenase inhibitors.
    Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
    Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine 2,3-Dioxygenase Activity During Acute Toxoplasmosis and the Suppressed T Cell Proliferation in Mice.
    Ufermann CM; Domröse A; Babel T; Tersteegen A; Cengiz SC; Eller SK; Spekker-Bosker K; Sorg UR; Förster I; Däubener W
    Front Cell Infect Microbiol; 2019; 9():184. PubMed ID: 31231617
    [No Abstract]   [Full Text] [Related]  

  • 15. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
    Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
    Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular expression, activity and function of indoleamine 2,3-dioxygenase-1 following cerebral ischaemia-reperfusion in mice.
    Jackman KA; Brait VH; Wang Y; Maghzal GJ; Ball HJ; McKenzie G; De Silva TM; Stocker R; Sobey CG
    Naunyn Schmiedebergs Arch Pharmacol; 2011 May; 383(5):471-81. PubMed ID: 21359968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Li A; Barsoumian HB; Schoenhals JE; Caetano MS; Wang X; Menon H; Valdecanas DR; Niknam S; Younes AI; Cortez MA; Welsh JW
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):903-912. PubMed ID: 30905636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of indoleamine 2,3-dioxygenase by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model.
    Lim JY; Lee SE; Park G; Choi EY; Min CK
    Exp Hematol; 2014 Oct; 42(10):862-6.e3. PubMed ID: 24971697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.